Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma
| Autor: | Kantha R. Kolla, Sant P. Chawla, Mahesh Seetharam |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Eribulin Mesylate Cancer Research Halichondrin B Anthracycline Metastatic Liposarcoma Antineoplastic Agents 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Biomarkers Tumor Animals Humans Medicine Furans Clinical Trials as Topic Taxane business.industry Soft tissue sarcoma Sarcoma General Medicine Ketones medicine.disease Metastatic breast cancer 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis Cancer research Immunotherapy business Eribulin |
| Zdroj: | Future Oncology. 14:1531-1545 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2017-0461 |
| Popis: | Eribulin is a structurally simplified, synthetic macrocyclic ketone analog of halichondrin B, which is a natural, polyether macrolide derived from marine sponges. Eribulin exerts its cytotoxicity by its unique microtubule dynamics inhibitory action. Eribulin was approved in 2010 by the US FDA as a third-line therapy for metastatic breast cancer patients previously treated with an anthracycline and a taxane. In 2016, it was approved for treatment of metastatic liposarcoma for patients who have progressed with anthracycline treatment. In this article, we review the pharmacokinetics, mechanism of action of eribulin with focus on preclinical and clinical data in sarcoma and also the role of miRNAs in soft tissue sarcomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|